Background: The role of immunization with bacillus Calmette-Guérin (BCG) in the prevalence of asthma, hay fever and atopic dermatitis is not definitely established and seems to be influenced by ethnic background. The aim of this study was to analyze the relationship between this immunization and the prevalence of those diseases in a homogeneous population of Spanish schoolchildren. Methods: The International Study of Asthma and Allergies in Childhood (ISAAC) core and environmental questionnaires were used in four different centers of the Spanish North Atlantic coast. Bilbao, San Sebastián and Asturias have a universal BCG immunization policy during the first days of life, whereas La Coruña discontinued this practice in 1989. Except for this center, immunization coverage was above 90%. A random sample of schools of Asturias or all schools in the city district (rest of centers) with children 6 and 7 years old was surveyed. Results: The participation rate was above 70%. After excluding those children born outside Spain, the numbers were 6,762 immunized and 2,828 nonimmunized. After adjusting for gender, age, smoking habits of the father and mother, truck traffic near the household, older and younger siblings and having a cat or a dog during the first year of the child’s life, the adjusted ORs of the BCG-immunized children suffering from asthma, hay fever and atopic dermatitis were respectively 0.87 (95% CI 0.76–1.00), 0.87 (0.75–1.01) and 0.89 (0.76–1.05). Conclusions: BCG immunization offers a weak but significant protection against asthma and hay fever in Spanish schoolchildren.

Keywords:
BCG, Asthma, Hay fever, Atopic dermatitis, Schoolchildren, Spain
1.
Shirakawa T, Enomoto T, Shimazu S, Hopkin JM: The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77–79.
2.
Janssen R, Kruisselbrink A, Hoogteijling L, Lamb JR, Young DB, Thole JE: Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology 2001;102:441–449.
3.
Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS: A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 1999;97:515–521.
4.
Herz U, Gerhold K, Gruber C, Braun A, Wahn U, Renz H, Paul K: BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol 1998;102:867–874.
5.
Lowry PW, Ludwig TS, Adams JA, Fitzpatrick ML, Grant SM, Andrle GA, Offerdahl MR, Cho SN, Jacobs DR Jr: Cellular immune responses to four doses of percutaneous bacille Calmette-Guérin in healthy adults. J Infect Dis 1998;178:138–146.
6.
Sander B, Skansen-Saphir U, Damm O, Hakansson L, Andersson J, Andersson U: Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin. Immunology 1995;86:512–518.
7.
Choi IS, Koh YI: Therapeutic effects of BCG vaccination in adult asthmatic patients: A randomized, controlled trial. Ann Allergy Asthma Immunol 2002;88:584–591.
8.
Choi IS, Koh YI: Effects of BCG revaccination on asthma. Allergy 2003;58:1114–1116.
9.
Vargas MH, Bernal-Alcantara DA, Vaca MA, Franco-Marina F, Lascurain R: Effect of BCG vaccination in asthmatic schoolchildren. Pediatr Allergy Immunol 2004;15:415–420.
10.
Alm JS, Lilja G, Pershagen G, Scheynius A: Early BCG vaccination and development of atopy. Lancet 1997;350:400–403.
11.
Anderson HR, Poloniecki JD, Strachan DP, Beasley R, Bjorksten B, Asher MI: Immunization and symptoms of atopic disease in children: Results from the International Study of Asthma and Allergies in Childhood. Am J Public Health 2001;91:1126–1129.
12.
Gruber C, Kulig M, Bergmann R, Guggenmoos-Holzmann I, Wahn U: Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early bacille Calmette-Guérin-vaccinated and nonvaccinated children. Pediatrics 2001;107:E36.
13.
Krause TG, Hviid A, Koch A, Friborg J, Hju ler T, Wohlfahrt J, Olsen OR, Kristensen B, Melbye M: BCG vaccination and risk of atopy. JAMA 2003;289:1012–1015.
14.
Strannegard IL, Larsson LO, Wennergren G, Strannegard O: Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy 1998;53:249–254.
15.
Omenaas E, Jentoft HF, Vollmer WM, Buist AS, Gulsvik A: Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults. Thorax 2000;55:454–458.
16.
Jentoft HF, Omenaas E, Eide GE, Gulsvik A: Absence of relationship between tuberculin reactivity and asthmatic symptoms, level of FEV1 and bronchial hyperresponsiveness in BCG vaccinated young adults. Allergy 2002;57:336–340.
17.
Gruber C, Meinlschmidt G, Bergmann R, Wahn U, Stark K: Is early BCG vaccination associated with less atopic disease? An epidemiological study in German preschool children with different ethnic backgrounds. Pediatr Allergy Immunol 2002;13:177–181.
18.
Aaby P, Shaheen SO, Heyes CB, Goudiaby A, Hall AJ, Shiell AW, Jensen H, Marchant A: Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy 2000;30:644–650.
19.
Salas A, Comas D, Lareu MV, Bertranpetit J, Carracedo A: mtDNA analysis of the Galician population: A genetic edge of European variation. Eur J Hum Genet 1998;6:365–375.
20.
Schanfield MS, Baylerian R, Maiquez J, Carbonell F: Immunoglobulin allotypes in European populations. IV. Gm, Am and Km allotypic markers in Valencia, Spain. J Immunogenet 1981;8:529–532.
21.
Arnaiz-Villena A, Rodriguez DC, Vela F, Pascual JC, Cervero J, Bootello A: HLA antigens in a sample of the Spanish population: Common features among Spaniards, Basques, and Sardinians. Hum Genet 1981;58:344–348.
22.
Calderon R, Vidales C, Rebato E, Pena JA: ABH antigen secretion in Basques and the spatial variation pattern of the secretor locus in Spain. Gene Geogr 1991;5:61–68.
23.
Mommers M, Weishoff-Houben M, Swaen GM, Creemers H, Freund H, Dott W, van Schayck CP: Infant immunization and the occurrence of atopic disease in Dutch and German children: A nested case-control study. Pediatr Pulmonol 2004;38:329–334.
24.
Alm JS, Sanjeevi CB, Miller EN, Dabadghao P, Lilja G, Pershagen G, Blackwell JM, Scheynius A: Atopy in children in relation to BCG vaccination and genetic polymorphisms at SLC11A1 (formerly NRAMP1) and D2S1471. Genes Immun 2002;3:71–77.
25.
Marks GB, Ng K, Zhou J, Toelle BG, Xuan W, Belousova EG, Britton WJ: The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: An historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. J Allergy Clin Immunol 2003;111:541–549.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.